SEC Form 3 · accession 0000899243-19-005076
Kaleido Biosciences, Inc. · KLDO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alison Frances Lawton
Officer — See Remarks · Director
Period of report
Feb 27, 2019
Accepted (ET)
Feb 27, 2019 · 6:23 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001751299
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 165,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $2.22 | holding | — | — | — | — | Dec 5, 2027 | Common Stock | 162,500 | — | D |
| Stock Option (Right to Buy)F2 | $10.28 | holding | — | — | — | — | Aug 15, 2028 | Common Stock | 817,948 | — | D |
Explanation of responses
- F1Subject to vesting per agreement with the Company.
- F225% of this option shall vest and become exercisable on August 16, 2019, with the remainder subject to vesting per agreement with the Company.
Remarks
President and Chief Executive Officer Exhibit 24.1: Power of Attorney